Year 2014 / Volume 106 / Number 3
Letter to the Editor
New contributions to consensus on biosimilars

228-229

Federico Argüelles-Arias, Manuel Barreiro-de-Acosta, Fernando Carballo, Joaquín Hinojosa y Teresa Tejerina

Abstract
Dear Editor,
Following the initial publication by the Multidisciplinary Working Group on Biosimilars and Inflammatory Bowel Disease (IBD) of Sociedad Española de Patología Digestiva (SEPD) and Sociedad Española de Farmacología (SEF) of a position statement regarding the anticipated launch of biosimilars approximately one year ago in Revista Española de Enferme- dades Digestivas (REED) (1), and after the publication of some other position statements on this subject by other societies, including the Canadian Association of Gastroenterology (2) and ECCO (3) (along the same lines as ours), the European Medicines Agency (EMA) has now authorized the first such monoclonal antibodies for use in the management of IBD (4). This has led our Group to review the aforementioned statement.
Share Button
New comment
Comments
No comments for this article
Related articles
Citation tools
Federico Argüelles-Arias, Manuel Barreiro-de-Acosta, Fernando Carballo, Joaquín Hinojosa y Teresa Tejerina. New contributions to consensus on biosimilars. 228-229


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 75 visits.
This article has been downloaded 75 times.
Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology